A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX� After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma
Read time: 1 mins
Last updated:28th Jun 2013
To evaluate the efficacy of maintenance therapy with the single-agent PankoMab-GEX� compared to placebo as assessed by progression free survival(PFS) following chemotherapy in patients with recurrent epithelial ovarian carcinoma.
|Study start date||2013-06-28|